Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.

Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD.

Cancer. 2012 Dec 1;118(23):5894-902. doi: 10.1002/cncr.27582.

2.

Tivantinib in hepatocellular carcinoma.

Trojan J, Zeuzem S.

Expert Opin Investig Drugs. 2013 Jan;22(1):141-7. doi: 10.1517/13543784.2013.741586. Review.

PMID:
23167786
3.

Tivantinib: critical review with a focus on hepatocellular carcinoma.

Rota Caremoli E, Labianca R.

Expert Opin Investig Drugs. 2014 Nov;23(11):1563-74. doi: 10.1517/13543784.2014.949339. Review.

PMID:
25307444
4.

Tivantinib (ARQ197) in hepatocellular carcinoma.

Porta C, Giglione P, Ferrari A, Reversi F, Liguigli W, Imarisio I, Ganini C.

Expert Rev Anticancer Ther. 2015 Jun;15(6):615-22. doi: 10.1586/14737140.2015.1050383. Review.

PMID:
26035719
5.

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date.

Pievsky D, Pyrsopoulos N.

J Hepatocell Carcinoma. 2016 Nov 15;3:69-76. Review.

6.

MiT transcription factor associated malignancies in man.

Davis IJ, Fisher DE.

Cell Cycle. 2007 Jul 15;6(14):1724-9. Review.

PMID:
17630504
Items per page

Supplemental Content

Support Center